Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Challenges in cardiac tissue engineering

Vunjak-Novakovic G., Tandon N., Godier A., Maidhof R., Marsano A., Martens TP.

Narrative Review on Cardiovascular Disease, published in Tissue Eng Part B Rev (2010) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Tissue Eng Part B Rev (2010)
Reported sample size
—
Source database
Europe PMC
PMID
19698068
PMCID
PMC2946883
DOI
10.1089/ten.teb.2009.0352
Citations
308

Abstract (original English)

Cardiac tissue engineering aims to create functional tissue constructs that can reestablish the structure and function of injured myocardium. Engineered constructs can also serve as high-fidelity models for studies of cardiac development and disease. In a general case, the biological potential of the cell-the actual "tissue engineer"-is mobilized by providing highly controllable three-dimensional environments that can mediate cell differentiation and functional assembly. For cardiac regeneration, some of the key requirements that need to be met are the selection of a human cell source, establishment of cardiac tissue matrix, electromechanical cell coupling, robust and stable contractile function, and functional vascularization. We review here the potential and challenges of cardiac tissue engineering for developing therapies that could prevent or reverse heart failure.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MyocardiumHeartAnimalsHumansHeart TransplantationOrgan Culture TechniquesTissue EngineeringPerfusionElectric StimulationModels, Biological

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research